Deubiquitinase inhibitor PR-619 potentiates colon cancer immunotherapy by inducing ferroptosis
{{output}}
A substantial number of colon cancer patients do not benefit from immunotherapy using programmed cell death 1 (PD1) antibodies. Therefore, combination therapy drugs are required to improve the efficacy of colon cancer immunotherapy. Recent studies have shown t... ...
